FeesSafety
Pluang+

CorVel reports Q2 revenue up 11% to $267M and EPS up 24% to $0.67, driven by tech and client growth.

Company Fundamentals
03 Nov 2026, 13:15 WIB
GlobeNewsWire
View Source
Bullish
CorVel reports Q2 revenue up 11% to $267M and EPS up 24% to $0.67, driven by tech and client growth.

CorVel Corporation announced its Q2 2027 results with revenues rising 11% to $267 million and diluted earnings per share increasing 24% to $0.67 compared to the same quarter last year. The company highlighted strong growth in workers' compensation and liability businesses, supported by new customer wins and deeper client relationships. Innovations in AI and digital tools are enhancing claims management efficiency and cost control. CorVel ended the quarter with $270 million in cash and repurchased $18.1 million in stock, positioning itself for continued growth and market expansion.

CorVel Corporation's Q2 2027 results provide context as of Nov 03, 2026 17:51 WIB. For readers following health-sector stocks, here is Pluang's market snapshot: of 150 priced US health-sector stocks, 70 rose and 69 fell today. Notable movers include ACB at USD 4.34 with a 1-day change of +2.84%, BKD at USD 10.16 with -2.68%, and ADMA at USD 11.35 with +2.62% and a balanced Pluang order activity of 50% Sell / 50% Buy.

More News

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex names Terrie Kellmeyer CEO to lead clinical growth and FDA engagement

Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...

Company Fundamentals
Bullish
1 hour ago
Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology to present at UBS Global Biopharma Conference on Nov 16-17, 2026

Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...

Market News
Bullish
1 hour ago
Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond expands smart city tech with LiDAR-powered operational twins and AI collaborations

Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...

Market News
Bullish
1 hour ago
Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones schedules Q3 2026 earnings call for Nov 4, open to investors and analysts.

Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...

Company Fundamentals
Neutral
2 hours ago
Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones to hold Q3 2026 financial results conference call on Nov 4

Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App